Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is Segmented by Type of Infection (Hospital Acquired ABSSI, Community-acquired ABSSI), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (USD million) for the above segments.

Market Snapshot

Acute Bacterial Skin And Skin Structure Infection Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: Asia-Pacific
CAGR: 9.9 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is expected to grow at a registered CAGR of 9.9% during the forecast period, 2022-2027.

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the acute bacterial skin and skin structure infection (ABSSSI) market. However, according to the study titled "Hospital-acquired Skin and Skin-structure Infection in COVID-19 Infected Patient with Prolonged Hospitalization" published in the Acta Medica Indonesia in January 2021, bacterial skin and skin structure infections are worsened in the COVID-19 patient. They are required to prolong hospitalization rise in the treatment options demand, thereby anticipating market growth during COVID-19. Thus, the acute bacterial skin and skin structure infection (ABSSSI) market was significantly impacted by COVID-19.

The rising prevalence and awareness of acute bacterial skin and skin structure infection, as well as increased research and development activities by pharmaceutical and biopharmaceutical companies to supply new products and novel treatments, all contribute to the global ABSSSI market's growth.

Two of the most common bacteria that cause Acute Bacterial Skin and Skin Structure Infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S. aureus. Gram-negative bacteria, other Streptococcus species, and Enterococcus faecalis are less common causes. According to the study titled "Management of acute bacterial skin and skin structure infections in India: are we equipped to meet the challenges of the growing menace of methicillin-resistant Staphylococcus aureus?" published in the International Surgery Journal in July 2020, Staphlococcus aureus (Staphylococcus aureus) is a Gram-positive facultative anaerobic bacteria that colonizes human skin and nasal passages. Invasive S. aureus infections have become more common in recent decades and are linked to poor outcomes and high mortality rates. S. aureus causes nearly one-third of all acute bacterial skin and skin structure infections, with methicillin-resistant Staphylococcus aureus (MRSA) accounting for most of these infections.

However, growing pipeline development activity and rising research and development expenditure by pharmaceutical and biotechnology companies are anticipated to drive the market over the forecast period. For instance, as per the clinicaltrials.gov in May 2021, Ceftobiprole Medocarial under Phase III trials is an effective treatment option for acute bacterial skin and skin structure infections. Moreover, according to the same source posted on October 2020, an intravenous formulation of TNP-2092 from TenNor Pharmaceutical limited is also under clinical development for treating acute bacterial skin and skin structure infections (ABSSSI).

Furthermore, growing product launches and various activities by the key market players such as mergers and acquisitions, collaborations, and partnerships are anticipated to drive the market. For instance, in March 2021, Kimyrsa (oritavancin; Melinta Therapeutics) was approved by the Food and Drug Administration (FDA) to treat adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms.

Thus, all these factors are expected to boost the market over the forecast period.

Scope of the Report

Acute Bacterial Skin and Skin Structure Infection is a bacterial infection of the skin and associated tissues. The Food and Drug Administration (FDA) defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ≥38°C (100.4°F). Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is Segmented by Type of Infection (Hospital Acquired ABSSI, Community-acquired ABSSI), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

Type of Infection
Hospital Acquired ABSSI
Community acquired ABSSI
Route of Administration
Oral
Parenteral
Topical
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United states
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Hospital Acquired ABSSI is is Expected to Hold Significant Market Share in the Process Component Segment

Infections acquired in a healthcare setting that was not present before the contact are known as healthcare-associated infections (HCAIs). They may cause (or prolong) stays in acute care hospitals, increase medical and economic burdens, and cause morbidity and mortality. For instance, according to the study titled "Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections," published in the Journal of Antimicrobial Chemotherapy in November 2021, Adult inpatients in National Health Service hospitals in England are estimated to have 834,000 Healthcare-associated infections (HCAIs) each year, accounting for 7.1 million occupied hospital bed days (21 percent of total annual bed days) and a EUR 2.7 billion economic burden.

Furthermore, according to the same source, the prevalence of HCAI is estimated to be 6.0 percent. The most common infections were skin and soft tissue infections (SSTIs), which included surgical site infections (SSIs). Patients in intensive care units had the highest rate of hospital-acquired ABSSSI. Thus growing prevalence of hospital-acquired infection is expected to boost the segment growth.

However, various strategic activities by the key market to boost the market include product launches, pipeline development, and merger and acquisition. For instance, in July 2021, Delafloxacin was approved in the United Kingdom to treat acute bacterial skin and skin structure infections (ABSSSI) in adults when other antibacterial agents are considered inappropriate for the initial treatment of these infections.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market

North America Holds a Significant Share in the Market and Expected to do Same during the Forecast Period

North America will continue to dominate the acute bacterial skin and skin structure infection market during the forecast period due to extensive research and development activity, R & D spending, product pipeline, and novel product launches.

For instance, as per the ClinicalTrials.gov posted on January 2020, study title "Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)"under the clinical development for the drug Dalbavancin from the allergen pharmaceutical in the United States. Thus, the number of drugs under clinical trials is expected to increase the product launch over the projected period of anticipated market growth.

However, the growing product pipeline and product approval by regulatory authorities are expected to boost the market over the forecast period. For instance, in July 2021, the Food and Drug Administration (FDA) expanded the approval of Dalvance (dalbavancin) to include treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms in pediatric patients. Previously, the treatment was only approved for adults 18 and older. Additionally, in July 2019, Basilea Pharmaceutica Ltd. reported positive topline results for the phase 3 TARGET study, evaluating ceftobiprole in treating patients with acute bacterial skin and skin structure infections (ABSSSI).

Thus, all such factors are expected to boost the market in North America over the forecast period.

Acute Bacterial Skin And Skin Structure Infection Market Growth

Competitive Landscape

The gram-positive Bacterial Infections market is moderately competitive. The market is comprised of many small and large market players. However, with technological advancements and product innovations, mid-size to smaller companies increase their market presence by introducing new products at lower prices. Some of the market players are Glenmark Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd), and Cadila Healthcare Ltd.

Recent Developments

In January 2022, Paladin Labs Inc., a subsidiary of Endo International PLC launched the Xydalba (dalbavancin for injection), a 30-minute intravenous (IV) therapy for acute bacterial skin and skin structure infections (ABSSSI) that can be administered as a single- or two-dose.

In July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, reported the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence and Awareness of Acute Bacterial Skin and Skin Structure Infection

      2. 4.2.2 Increasing Pipeline Development Activities

      3. 4.2.3 Rising Healthcare Spending Across the World

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Policies by Government Bodies, and Patent Expiration

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 Type of Infection

      1. 5.1.1 Hospital Acquired ABSSI

      2. 5.1.2 Community acquired ABSSI

    2. 5.2 Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Parenteral

      3. 5.2.3 Topical

    3. 5.3 Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United states

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Paratek Pharmaceuticals, Inc.,

      2. 6.1.2 Melinta Therapeutics, Inc.,

      3. 6.1.3 Allergan plc,

      4. 6.1.4 Merck & Co., Inc.,

      5. 6.1.5 AccordHealthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.),

      6. 6.1.6 Sandoz Inc. (a subsidiary of Novartis),

      7. 6.1.7 Glenmark Pharmaceuticals Ltd

      8. 6.1.8 Cadila Healthcare Ltd.,

      9. 6.1.9 Teva Pharmaceutical Industries Ltd.

      10. 6.1.10 Pfizer Inc.

      11. 6.1.11 Cumberland pharmaceutical inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market market is studied from 2019 - 2027.

The Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is growing at a CAGR of 9.9% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia-Pacific holds highest share in 2021.

Paratek Pharmaceuticals, Inc., , Melinta Therapeutics, Inc., , Allergan plc,, Merck & Co., Inc., , Cumberland pharmaceutical Inc are the major companies operating in Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!